Skip to main content
editorial
. 2016 Nov 29;6(1):1–12. doi: 10.1159/000449342

Table 7.

CheckMate 040 dose-escalation cohort (n=48) investigator-assessed best overall response (RE CIST v1.1)

Uninfected (n=23) HCV (n=10) HBV (n=15) Total (n=48)
Objective response, n (%) 3 (13) 3 (30) 1 (7) 7 (15)
CR 2 (9) 1 (10) 0 3 (6)
PR 1 (4) 2 (20) 1 (7) 4 (8)
SD 13(57) 5 (50) 6 (40) 24 (50)
PD 6 (26) 2 (20) 7 (47) 15 (31)
Not evaluable 1 (4) 0 1 (7) 2 (4)
Ongoing response, n (%) 1 (33) 0 0 1 (14)

Reproduced with permission from El-Khoueiry AB, et al. [29]